RESUMO
Lutropin alfa is the first and only recombinant human form of luteinizing hormone (LH) developed for use in the stimulation of follicular development. Dose-finding studies revealed a significant dose-dependent increase in the rate of optimal follicular development among women with hypogonadotropic hypogonadism and profound LH deficiency (<1.2 IU/L) who received subcutaneous lutropin alfa 0-225 IU/day plus follitropin alfa. Similarly, in a double-blind, randomized study, the rate of optimal follicular development was significantly higher in women with hypogonadotropic hypogonadism and profound LH deficiency receiving subcutaneous lutropin alfa 75 IU/day plus follitropin alfa than in those receiving placebo plus follitropin alfa. Lutropin alfa with follitropin alfa may also be of benefit in certain subgroups of normogonadotropic women (e.g. those with an inadequate response to prior follitropin alfa monotherapy, those aged >or=35 years, and those with profound LH downregulation or who required excessive exogenous follitropin alfa). However, one study in older women (>or=35 years) did not show any advantage of lutropin alfa supplementation. Once-daily subcutaneous lutropin alfa was generally well tolerated in hypogonadotropic hypogonadal women, with the majority of adverse events being of mild to moderate severity.
Assuntos
Fármacos para a Fertilidade Feminina , Subunidade alfa de Hormônios Glicoproteicos , Quimioterapia Combinada , Feminino , Fármacos para a Fertilidade Feminina/farmacocinética , Fármacos para a Fertilidade Feminina/farmacologia , Fármacos para a Fertilidade Feminina/uso terapêutico , Hormônio Foliculoestimulante Humano/uso terapêutico , Subunidade alfa de Hormônios Glicoproteicos/farmacocinética , Subunidade alfa de Hormônios Glicoproteicos/farmacologia , Subunidade alfa de Hormônios Glicoproteicos/uso terapêutico , Humanos , Hipogonadismo/tratamento farmacológico , Infertilidade Feminina/tratamento farmacológico , Injeções Subcutâneas , Hormônio Luteinizante/deficiência , Indução da Ovulação/métodos , Proteínas Recombinantes/farmacocinética , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêuticoRESUMO
El análisis de la hormona tiroestimulante (TSH) de tercera generación permite la diferenciación de pacientes con hipertiroidismo real y pacientes con niveles suprimidos de TSH asociados con otras patologías, lo cual era imposible determinar con los análisis de primera y segunda generación